Clinical Trials
Aduro’s lead program, a combination immunotherapy comprised of its novel GVAX Pancreas and CRS-207 technologies, is being evaluated in a 240-patient Phase 2b ECLIPSE trial in patients with metastatic pancreatic cancer.

CONTINUE READING »
Technology
Aduro is harnessing the immune system to treat cancer.  Aduro's technologies are designed to activate both innate and adaptive immunity to generate a potent and long-lasting response against cancer.   

CONTINUE READING »
News
  • October, 30 2014  | 5 Lifesaving Medical Breakthroughs (see #2)  READ IT HERE
  • October, 23 2014  | Aduro presents updated interim results from Phase 1b clinical trial in mesothelioma at International Mesothelioma Interest Group Conference  READ IT HERE
  • October, 16 2014  | Aduro expands collaboration with Johnson & Johnson Innovation and Janssen for lung cancer immunotherapies  READ IT HERE
  • October, 15 2014  | Aduro BioTech announces interim Phase 1B clinical data of CRS-207 for the treatment of mesothelioma accepted for oral presentation at the International Mesothelioma Interest Group conference  READ IT HERE
  • October, 09 2014  | Aduro BioTech’s Chief Scientific Officer, Thomas W. Dubensky, Jr., Ph.D., a featured speaker on action of vaccine adjuvants at Keystone Symposia  READ IT HERE
  • September, 22 2014  | Aduro BioTech named one of Fierce 15 leading biotech companies in 2014  READ IT HERE
SEE MORE NEWS »
Copyright 2011-2013 Aduro Biotech. All rights reserved.
Privacy Policy  |  Terms of Use